Search Results
Your search for ,aLl matches 18309 pages
Showing 351 - 400First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
In an interim analysis of a Chinese phase III trial (HARMONi-6) reported in The Lancet, Chen et al found that the combination of ivonescimab—a bispecific antibody targeting PD-1 and VEGF—plus chemotherapy prolonged progression-free survival vs tislelizumab—an anti–PD-1 monoclonal antibody—plus...
Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer
In an updated analysis published in The New England Journal of Medicine, Roobol et al reported long-term findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) on the survival benefit of prostate-specific antigen (PSA) screening. The study, which was initiated in 1993, ...
Extensive LA-Area Fires Altered Blood Proteins in Firefighters
Researchers have found that firefighters who battled the massive urban fires in the Los Angeles area in January 2025 developed physiologic changes that may increase their risk of diseases, including cancer. The research, which was published by Furlong et al in the Journal of Occupational and...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall survival vs regorafenib in patients with previously treated relapsed or refractory metastatic colorectal...
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study Details In the single-arm,...
Experts Outline Roadmap for Clinical Implementation of AI in Pediatric CNS Tumor Management
A subcommittee of the RAPNO (Response Assessment in Pediatric Neuro-Oncology) consortium that is focused on artificial intelligence (AI-RAPNO) has released guidance on the responsible implementation of AI in pediatric neuro-oncology in the form of a two-part policy review published in The Lancet...
Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer
“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born and raised in what is now Bangladesh, he experienced the death of his mother at the young age of ...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
Malignant Melanoma: Addition of Whole-Body Imaging in Postsurgery Follow-up
In an interim analysis of a Swedish phase III study (TRIM) reported in The Lancet Oncology, Ladjevardi et al found no improvement in outcomes with the addition of whole-body imaging to physical examination in a follow-up of patients undergoing radical surgery for stage IIB-C or III cutaneous...
Addition of Abemaciclib to Abiraterone in mCRPC
In a phase III study (CYCLONE 2) reported in The Lancet Oncology, Smith et al found that the addition of abemaciclib to abiraterone did not significantly improve radiographic progression–free survival in men with metastatic castration-resistant prostate cancer (mCRPC). Study Details In the...
Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma
In a Chinese phase II/III trial (CARES-009) reported in The Lancet, Wang et al found that the addition of perioperative camrelizumab (PD-1 inhibitor) and rivoceranib (VEGFR2 inhibitor) to surgical resection significantly improved event-free survival in patients with hepatocellular carcinoma at...
Carboplatin Plus Taxane-Anthracycline Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Gupta et al found that the addition of carboplatin to neoadjuvant sequential taxane-anthracycline chemotherapy did not improve event-free survival, the primary endpoint, in patients with triple-negative breast...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Jobs Commonly Held by Immigrant Women May Put Them at Increased Risk for Breast Cancer
Many immigrant women in the United States work in jobs that may expose them to chemicals linked to breast cancer, according to a recent study led by Silent Spring Institute. The analysis is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among...
Investigational Antibody-Drug Conjugate in Previously Treated SCLC
About 13% of all lung cancers in the United States are small cell lung cancer (SCLC), and approximately 87% are non–small cell lung cancer (NSCLC). Together, these lung cancers are the second most common cancer diagnosed in both men and women, excluding skin cancer. Usually a very aggressive...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Glofitamab Plus Polatuzumab Vedotin in Relapsed or Refractory Large B-Cell Lymphoma
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Hutchings et al found that the combination of glofitamab and polatuzumab vedotin was associated with high activity in patients with relapsed or refractory large B-cell lymphoma, including high-grade B-cell lymphoma. Study Details...
Preneoplastic and Neoplastic Small Lymphocytic Proliferations
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the key epidemiologic, pathologic, diagnostic, and prognostic aspects of chronic...
Zenocutuzumab Potential Explored in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab-zbco yielded clinical activity in more than one-third of patients with cholangiocarcinoma and an NRG1 fusion, according to findings from the phase II eNRGy trial presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract ...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Ruxolitinib in Steroid-Refractory Acute GVHD: Final Analysis From REACH2
As reported in the Journal of Clinical Oncology by Mohty et al, the final analysis of the phase III REACH2 trial indicates that ruxolitinib provided efficacy advantages over the best available therapy (BAT) in patients with steroid-refractory acute graft-vs-host disease (GVHD) after allogeneic...
Pembrolizumab Plus Chemotherapy Without Radiotherapy in Unresectable Locally Advanced NSCLC With High PD-L1 Expression
In a Japanese phase II trial (Evolution) reported in The Lancet Oncology, Hata et al found that pembrolizumab plus platinum-based chemotherapy without radiotherapy was active in unresectable locally advanced non–small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50%. Study...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma: 9-Year Follow-Up of CheckMate 238
As reported at the latest ESMO Congress and in The New England Journal of Medicine by Ascierto et al, the 9-year follow-up of the phase III CheckMate 238 trial showed a continued recurrence-free survival benefit with adjuvant nivolumab vs ipilimumab in patients with resected stage IIIB–C or IV...
Disitamab Vedotin Plus Toripalimab vs Chemotherapy in HER2-Expressing Advanced Urothelial Cancer
In a Chinese phase III trial (RC48-C016) reported at the recent ESMO Congress and in The New England Journal of Medicine, Sheng et al found that the combination of the HER2-directed antibody-drug conjugate disitamab vedotin and the PD-1 inhibitor toripalimab-tpzi improved progression-free survival...
Sacituzumab Tirumotecan in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (OptiTROP-Lung-04) reported at the recent ESMO Congress and published in The New England Journal of Medicine, Fang et al found that monotherapy with sacituzumab tirumotecan (sac-TMT)—an antibody-drug conjugate targeting trophoblast cell–surface antigen 2—was associated...
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
Revumenib Approved by FDA for NPM1-Positive AML
On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj), a menin inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation, in adult and pediatric patients 1 year and older who have no...
Unresectable Stage III NSCLC: Addition of Simultaneous Durvalumab to Chemoradiotherapy
As reported in the Journal of Clinical Oncology by Bradley et al, the phase III PACIFIC-2 trial showed no significant progression-free survival benefit with the simultaneous addition of durvalumab to concurrent platinum-based chemoradiotherapy (cCRT) in patients with unresectable stage III...
Risk Factors for Valvular Heart Disease Among Childhood Cancer Survivors
In a study reported in JAMA Oncology, Glele et al identified potential risk factors for valvular heart disease (VHD) in a European cohort of long-term childhood cancer survivors. Study Details The nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer...
Cervical Cancer: SLNB Alone vs Lymphadenectomy
In a Chinese phase III trial (PHENIX) reported in The New England Journal of Medicine, Tu et al found that sentinel lymph node biopsy (SLNB) alone was noninferior in disease-free survival vs lymphadenectomy in women with early-stage cervical cancer and was associated with fewer surgical...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation
Circulating tumor DNA (ctDNA) was found to be a strong prognostic classifier for patients with stage III colon cancer following surgery, according to findings from the phase II/III DYNAMIC-III trial. Findings from the study presented at the European Society for Medical Oncology (ESMO) Congress 2025 ...
AGA Issues New Guideline Urging Risk-Based Surveillance in Barrett’s Esophagus
The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on surveillance of Barrett’s esophagus, the only known precursor to esophageal adenocarcinoma. The new guideline, which was published in Gastroenterology, emphasizes risk-based, individualized...
Clinical Usefulness of Linking Whole-Genome Data to Mortality Statistics in UK Patients With Breast Cancer
In a retrospective analysis reported in The Lancet Oncology, Black et al examined whether linking of comprehensive whole-genome sequencing (WGS) to mortality data could add prognostic value to standard clinical data and provide a rationale for use of targeted therapies. Study Details In the...
Obesity-Related Cancers Are Rising Among Both Younger and Older Adults Worldwide
Multiple studies have reported increasing rates of cancer in younger adults in individual countries, but have not included an international comparison across countries. To address this limitation, Berrington de Gonzalez et al conducted a surveillance study across 42 countries evaluating cancer...
State of the Hematology and Medical Oncologist Workforce in the United States
In a study reported in JCO Oncology Practice, Kirkwood et al identified recent changes in and characteristics of the hematologist/medical oncologist (oncologist) workforce in the United States, with the data revealing gaps in coverage according to age and other patient demographics. Study Details ...
New Guideline Reflects the Latest Evidence in Support of Postmastectomy Radiation Therapy for Patients With Breast Cancer
A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
The European Society for Medical Oncology (ESMO) has released its first set of recommendations for the use of artificial intelligence (AI) large language models in oncology practice, called the ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP). The guidance was...
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC
The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease, according to...
Muscle-Invasive Bladder Cancer: IMvigor011 Trial Investigates ctDNA-Guided Adjuvant PD-L1 Inhibition
Patients with muscle-invasive bladder cancer who tested positive for circulating tumor DNA (ctDNA) after cystectomy may benefit from immunotherapy with the PD-L1 inhibitor atezolizumab compared to placebo, whereas ctDNA-negative patients may potentially be spared unnecessary treatment. These...
ADC Improves Outcomes for Patients With Advanced TNBC Ineligible for Immunotherapy
Patients with an aggressive type of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody-drug conjugate (ADC) sacituzumab govitecan-hziy compared with standard chemotherapy. These...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
